정규장
Log in Sign up
BGMS
BGMS
Bio Green Med Solution Inc
7월 28일 1:03 PM ET (한국 7/29 02:03)
$0.92
+0.00 +0.42%

바이오그린메드솔루션(BGMS) is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독
시가총액
$5M
스몰캡
P/E
-
배당수익률
없음
52주 위치
2%
저점 +62% · 고점 -95%
애널리스트
보유
C+
Fundamental health
vs. Biotechnology 초소형주· based on 3 axes
수익성
산출 불가 (적자)
성장
Top 1%
밸류에이션
Top 73%
재무 안정
Top 64%
Index -P/E -EPS (ttm) -4.4Insider Own 42%Shs Outstand 5.5MPerf Week 2.09%
Market Cap 0.01BForward P/E -EPS next Y -Insider Trans -Shs Float 3.2MPerf Month 52.62%
Enterprise Value 0.00BPEG -EPS next Q -Inst Own 2.15%Short Float 3.16%Perf Quarter -5.35%
Income -0.01BP/S 3.34EPS this Y -Inst Trans 10.31%Short Ratio 0.04Perf Half Y -30.39%
Sales 0.00BP/B 0.75EPS next 5Y -ROA -250.43%Short Interest 0.10MPerf YTD -37.92%
Book/sh 1.22P/C 1.52EPS past 3/5Y 90.62% 77.93%ROE -288.07%52W High -94.9% ($18.00)Perf Year -94.27%
Cash/sh 0.61P/FCF -Sales past 3/5Y -ROIC -209.28%52W Low 62.22% ($0.57)Perf 3Y -99.96%
Dividend Est. -EV/EBITDA -EPS Y/Y TTM 99.4%Gross Margin 18.3%Volatility(W/M) 7.81% 13.64%Perf 5Y -99.99%
Dividend TTM -EV/Sales 1.14Sales Y/Y TTM 10792.86%Oper. Margin -238.49%ATR (14) 0.1Perf 10Y -100%
Dividend Ex-Date 2025/4/29Quick Ratio 5.87EPS Q/Q 57.48%Profit Margin -932.98%RSI (14) 51.83Recom 3
Dividend Gr. 3/5Y -Current Ratio 7.06Sales Q/Q -SMA20 0.35% ($0.92)Beta -0.38Target Price $240
Payout -Debt/Eq 0Earnings 2026/5/14SMA50 -0.29% ($0.92)Rel Volume 0.01Prev Close $0.92
Employees -LT Debt/Eq 0EPS/Sales Surpr. -SMA200 -30.9% ($1.33)Avg Volume(3M) 2.32MPrice $0.92
IPO 2004/3/16Option/Short No/YesTrades 72Volume 18,256Change 0.42%
Quarterly earnings trend SEC filings · USD
23.9
24.3
24.6
24.9
25.3
25.6
25.9
26.3
Revenue Net income 최근 분기: 매출 $1M · 순이익 $0M (YoY -143%)

📊 Bio Green Med Solution Inc (BGMS) Investment Analysis

What kind of company is Bio Green Med Solution Inc?

바이오그린메드솔루션(BGMS) 방어주
Healthcare · Biotechnology
Small-Cap — Low Volume, High Volatility

🧯 Bio Green Med Solutions () is a U.S. Nasdaq-listed micro-cap that originally operated a biopharmaceutical business but shifted its business focus to fire prevention and suppression equipment after acquiring Malaysian fire safety group Fitters Sdn. Bhd. in September 2025. Although its corporate name still falls under the healthcare sector classification, its actual operating activities are being reorganized around the distribution and servicing of fire safety products.

Learn more about Bio Green Med Solution Inc →
Market Cap
$0.0B
Approx. KRW 0.0 trillion
⚖️ 0% of Samsung Electronics
Market Cap Rank5665
IPO2004/03/16
Current Price$0.92 ≈ 1,260원
NASD · Malaysia

Key Events

⏰ Upcoming events
🔔 Earnings release
The next release date has not been announced yet.
🎯 Ex-dividend date
No scheduled dividends
📜 Recent events
🔔 Earnings release 2026년 5월 14일 (목) · 장 마감 후
🔔 Earnings release 2026년 3월 30일 (월) · 장 마감 후
🎯 Ex-div 2025년 4월 29일 (화)

Is it profitable?

Financially sound but profitability is low
Losses or thin margins — early-stage growth or weakening competitiveness
Profitability — How efficiently it makes money
Operating Margin
Profit kept from selling products and services (higher is better)
-238.5%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Net Margin
Share of revenue left after taxes and interest are paid
-933.0%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Gross Margin
Profit after subtracting raw-material costs only (signals product competitiveness)
18.3%
✓ 평균
My positionMid-range
Low range Average High range
Biotechnology 초소형주 Median 53.4% · Bottom 35%
💡 제조업 30%, IT/소프트웨어 50% 이상이면 우수 (업종별 편차 큼)
ROE
Annual return earned on shareholders' equity (15%+ is strong)
-288.1%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROA
Annual earnings relative to total company assets
-250.4%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
ROIC
Return generated per dollar invested in the business
-209.3%
✓ 적자
💡 적자 상태 — 수익을 내지 못하고 있습니다
Financial health — Debt & liquidity burden
Debt-to-Equity (D/E)
Debt relative to equity (lower is healthier)
0.00
✓ Very low debt
My positionTop 5%
Low range Average High range
Biotechnology Median 0.05
💡 일반적으로 1.0 이하면 건전, 1.5까지는 무난 (금융·유틸·REIT는 구조적으로 높음)
Current Ratio
Liquid assets available to cover liabilities due within a year
7.06
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.75
💡 1.5~3.0 적정, 1.0 미만이면 단기 유동성 주의
Quick Ratio
Liquid assets excluding inventory, available for immediate use
5.87
✓ 양호
My positionMid-range
Low range Average High range
Biotechnology Median 5.47
💡 1.0 이상이면 안전, 0.5 미만이면 주의
* Ratings reflect relative position vs. peer-group distribution (same sector & size) plus absolute guards (loss & risk thresholds).

What's the outlook?

Mixed Outlook
Positive and negative signals are mixed
애널리스트 목표가
$240.00
현재가 대비 +25987.0%
💡 12개월 이내 도달을 전망하는 애널리스트 컨센서스 평균
⚠ 이 데이터는 애널리스트 추정치이며 실제 결과와 다를 수 있습니다. 투자 결정은 추가 검토와 함께 하세요.

Did earnings meet expectations?

Insufficient historical earnings data

No analyzable past earnings releases have been collected yet.

Is it growing?

Average Growth
Mid-range within the industry
📊 How much has it grown? (actual results)
Past 3-Year EPS
Actual average annual EPS growth over the past 3 years
+90.6%
우수
My positionTop 5%
Low range Average High range
방어주 초소형주 Median 30.0% · Top 2%
Past 5-Year EPS
Actual average annual EPS growth over the past 5 years
+77.9%
우수
My positionTop 5%
Low range Average High range
방어주 초소형주 Median 16.4% · Top tier
* Forecast values are analyst consensus estimates. Ratings are determined by relative position vs. peer group of the same growth style and size.

Has the stock risen over the long term?

Long-term weakness — -168%p below the market
BGMS -100.0% · S&P 500 +68.3%
Excess return vs. market (price-based, ex-dividends)
5-year basis
vs S&P 500
-168.3%p
Significantly behind the market
vs Health Care (XLV)
-124.5%p
Significantly behind the sector average
1-year basis
vs S&P 500
-110.3%p
Significantly behind the market
vs Health Care (XLV)
-114.0%p
Significantly behind the sector average
Rank among peers
5-year return Lowest among peers Based on 245 peers
1-year return Lowest among peers Based on 315 peers
Current position within 52-week range
Low (-62.2%p) High (-94.9%p)
Current price is 62.2% above the 52-week low and 94.9% below the 52-week high
Recent risk (last 120 trading days)
Max drawdown
-60.0%
Annualized volatility
127.1%

Technical Indicators

Bollinger Bands · MACD · RSI · Stochastics · Ichimoku 5-line · recent 80-day series

Price · Bollinger Bands · Ichimoku Cloud

  • close
  • BB Upper
  • BB Mid
  • BB Lower
  • Tenkan
  • Kijun
  • Cloud (SpanA/B)

Bollinger Bands are upper and lower channels showing the closing price range (20 days · 2σ). Touching the upper band = overheated; touching the lower band = oversold. Ichimoku Cloud shows trend direction and strength through colored areas. Prices above the cloud indicate an uptrend; prices below indicate a downtrend. About Bollinger Bands →

🟢
Current diagnosis · 2026-07-27
Uptrend zone

Current price $0.92 above the midline ($0.92). Normal upward flow. Inside the Ichimoku cloud (neutral).

MACD (12 · 26 · 9) Expand ▼

An indicator that uses the difference between the short-term EMA (12) and long-term EMA (26) to identify trend reversals. When MACD rises above the Signal line, it is a buy signal (golden cross); when it falls below, it is a sell signal (death cross). About MACD →

🟢
Current diagnosis · 2026-07-27
Bullish momentum holding

MACD 0.005 > Signal 0.001 in positive zone + Hist positive (+0.003). Trend in progress.

RSI(14) · Stochastics %K(14) Expand ▼

RSI measures short-term buying and selling pressure on a scale of 0–100. 30 or below = oversold (a rebound may be possible); 70 or above = overbought (a pullback may be possible). Stoch %K similarly measures short-term momentum strength. RSI · Learn more about Stochastics →

🟢
Current diagnosis · 2026-07-27
Bullish zone

RSI 51.8 (above the neutral level of 50). Buying pressure leads, supporting a steady rise. Stoch %K is also 47.4.

※ "Current diagnosis" is an automated interpretation based on standard thresholds and is for reference only. Make your own comprehensive judgment before trading.

Is it attractive at this price?

Cheaper than peers in its industry
Cheap on Vs. Assets·Vs. Sales
💡 How to read this — Compare against peers in the same industry to see what the price is cheap or expensive relative to. Example: cheap vs. earnings = stock price is low relative to what the company earns; expensive vs. assets = stock price is high relative to assets on the balance sheet.
🏢 Vs. Assets Cheap
🧾 Vs. Sales Cheap
🏢 Vs. Assets
PBR Price-to-Book Ratio
Price vs. the company's asset value — below 1 trades cheaper than assets
0.75x
✓ Cheap
My positionMid-range
Low range Average High range
Biotechnology 초소형주 median 1.35x · Around the industry average
💡 PBR 1 미만이면 청산가치 이하 (금융·제조업에서 특히 의미, IT는 낮은 비중)
🧾 Vs. Sales
PSR Price-to-Sales Ratio
Market cap vs. revenue — lower is cheaper relative to sales
3.34x
✓ Cheap
My positionMid-range
Low range Average High range
Biotechnology 초소형주 median 11.24x · Around the industry average
💡 PSR 2 이하 저평가, 10 초과면 고평가 (고성장 기업일 때만 정당화)
Analyst target price (reference)
$240.00 vs. current price +25987.0%
* Valuation is the stock's relative position within the industry peer group (same sector and market-cap range). Even when valuation looks attractive, check the 'Profitability' and 'Growth' sections too.
As of: Recent snapshot · Peer group: Biotechnology 초소형주

Who owns it?

Ownership flow is positive
Institutional net buying +10.3% · Short interest light 3.2% · Short interest up +2.0pp over last 90d
📈 Recent trading flow (6 months)
🧑‍💼 Insiders (executives & directors)
0.0%
Insiders little change
🏦 Institutions (funds & investors)
+10.3%
Institutions large net buying
💡 Net change over the past 6 months. Shows how much insiders and institutions increased or reduced their holdings, in %.
👥 Holdings composition
🏦 Institutions 2.1%
Retail-led
Healthcare 초소형주 Median 14.2%
🧑‍💼 Insiders 42.0%
Founder/management large holders (strong skin-in-the-game)
Healthcare 초소형주 Median 16.1%
👤 Retail investors (estimated) 55.9%
Everyone excluding institutions and insiders
Institutions Insiders Retail (est.)
📉 Short-selling metrics
Short ratio
3.2%
Low — limited short-side pressure
Healthcare 초소형주 Median 3.9%
Past 90 days 📈 +2.0%p increase
Short interest days to cover
0.0 days
Days needed to close short positions using average trading volume
🧮 Share count
Total shares outstanding 5.5M주
Float (tradable shares) 3.2M주
* Insider/institutional flows are based on net changes over the past 6 months. Trend is cumulative over the past 90 days.

How much does it pay in dividends?

This company does not pay a dividend

It may be a growth-focused firm reinvesting profits into expansion. Consider this growth-stock profile when investing.

Compare Industry Peers

💡 vs. sector average ▲ Favorable / ▼ Unfavorable (Lower PER and PBR are better; higher ROE and dividend yield are better)
Sorted by market cap, largest first
StockMarket CapPERPBRROEDividend YieldChange
BGMS BGMS This Stock
$5.1M- 0.8 -288.07% - +0.4%
LLY
$1.13T43.1 36.2 107.64% 0.58% +0.1%
JNJ
$640.9B30.8 7.5 25.74% 2.02% +1.0%
ABBV
$453.9B126.7 - 15221.82% 2.67% -0.9%
UNH
$379.3B26.9 3.9 12.49% 2.16% -0.7%
MRK
$323.0B36.8 7.0 18.97% 2.5% -0.2%
Sector Avg-26.12.7-48.83%1.23%-
📊
See the market at a glance with a real-time dashboard Track premarket, regular, and after-hours quotes, screeners, and heatmaps on a single screen

FAQ

What kind of company is 바이오그린메드솔루션(BGMS)?

바이오그린메드솔루션(BGMS) belongs to the Healthcare sector and operates in the Biotechnology industry.

What is the market cap of BGMS?

The market cap of BGMS is approximately $5M, ranking 5,665 within its sector.

What is the 52-week high and low for BGMS?

BGMS has recorded a 52-week high of $18.00 and a low of $0.57.

시황 · 실적발표 · 매수매도 신호, 가장 먼저 받아보세요 🔔 구독

면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.